Vergelijking

BPC-157 vs. KPV

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Genezing

CAS-nr.

137525-51-0

67727-97-3

Molecuulmassa

1419.5 g/mol

342.4 g/mol

Halfwaardetijd

4 h

geen gegevens

Sequentie

GEPPPGKPADDAGLV

KPV

Werkingsmechanisme

BPC-157

Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.

KPV

KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.

Bewijsbasis

Hoogste bewijs

Diermodel

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	BPC-157	KPV
Australië	Verboden	—
Zwitserland	Niet goedgekeurd	—
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Alleen onderzoek	Alleen onderzoek

Volledige vermeldingen

BPC-157

Volledige vermelding →

KPV

Volledige vermelding →

Frequently asked questions

What is the difference between BPC-157 and KPV?: BPC-157 is classified as "Genezing", while KPV is classified as "Genezing". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, BPC-157 or KPV?: The highest available evidence level is "Diermodel" for BPC-157 and "Diermodel" for KPV. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of BPC-157 and KPV in Germany and the United States?: Duitsland: BPC-157 — Niet goedgekeurd, KPV — Niet goedgekeurd. Verenigde Staten: BPC-157 — Alleen onderzoek, KPV — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.

Country

BPC-157

KPV

Australië

Verboden

—

Zwitserland

Niet goedgekeurd

—

Duitsland

Niet goedgekeurd

Verenigde Staten

Alleen onderzoek

Frequently asked questions

What is the difference between BPC-157 and KPV?

BPC-157 is classified as "Genezing", while KPV is classified as "Genezing". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, BPC-157 or KPV?

The highest available evidence level is "Diermodel" for BPC-157 and "Diermodel" for KPV. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of BPC-157 and KPV in Germany and the United States?

Duitsland: BPC-157 — Niet goedgekeurd, KPV — Niet goedgekeurd. Verenigde Staten: BPC-157 — Alleen onderzoek, KPV — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.